Deal facts
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Announced
- 15 April 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- Canada
- Consideration
- cash
Sources
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic acquisition with full cash consideration. Both the announcement and completion of the deal occurred on 15 April 2026, indicating an immediate closing without a prolonged regulatory waiting period. This acquisition represents a significant capital deployment into the biopharmaceutical sector by the buyer.
The deal was finalised on the same day it was announced, suggesting a streamlined approval process or prior regulatory clearance. No specific details regarding the target's revenue or the specific assets acquired were reported in the available data. The transaction is now complete, with GSK plc having taken full ownership of the Canadian entity. The parties have concluded all necessary legal and financial obligations required to transfer control of the business.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
GSK plc to acquire 35Pharma Inc.
{ "headline": "GSK completes acquisition of 35Pharma Inc.", "issuer": "GSK (GSK)", "announcement_date": "2026-04-15T07:12:00", "category_code": "Completion of Acquisition", "body": "Disclaimer* \n\n Issued: 15 April 2026, London UK \n\n \n\n GSK completes acquisition of 35Pharma Inc. \n\n \n\n \n\n \n\n GSK plc (LSE/NYSE: GSK) today announced the completion of its acquisition of
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
GSK plc to acquire Nuvalent, Inc
GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…
- Buyer
- GSK plc
- Target
- Nuvalent, Inc
- Deal value
- USD 10,600,000,000
- Deal type
- strategic acquisition
Volex plc to acquire Kepler SignalTek Ltd
Volex plc has agreed to acquire Kepler SignalTek Ltd, a healthcare sector business based in the United Kingdom. The strategic acquisition was announced and completed on…
- Buyer
- Volex plc
- Target
- Kepler SignalTek Ltd
- Deal value
- USD 89,400,000
- Deal type
- strategic acquisition
Lixte Biotechnology Holdings, Inc. to acquire Nomad Transportable Power Systems, Inc.
Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction…
- Buyer
- Lixte Biotechnology Holdings, Inc.
- Target
- Nomad Transportable Power Systems, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Public Company Management Corporation to acquire Physicians Capital Management Corporation
Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…
- Buyer
- Public Company Management Corporation
- Target
- Physicians Capital Management Corporation
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Buyer history
GSK plc
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive